

**AMENDMENTS TO THE CLAIMS**

**1. (Currently Amended)** An epidermal growth factor receptor (EGFR)-derived peptide ~~or mutant peptide thereof~~ which is capable of inducing a cytotoxic T lymphocyte and an antibody specific for said peptide, wherein the EGFR-derived peptide consists of at least 8 consecutive amino acid residues derived from the amino acid sequence of EGFR<sub>800-809</sub> (SEQ ID NO: 1), EGFR<sub>124-132</sub> (SEQ ID NO: 2), EGFR<sub>54-62</sub> (SEQ ID NO: 3), EGFR<sub>479-488</sub> (SEQ ID NO: 4) or EGFR<sub>1138-1147</sub> (SEQ ID NO: 5).

**2. (Cancelled)**

**3. (Currently Amended)** A polypeptide consisting of 8 to 50 amino acid residues, which comprises the peptide of Claim 1 ~~or 2~~ and is capable of inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

**4. (Withdrawn - Currently Amended)** A nucleic acid molecule encoding the peptide of Claim 1 ~~or 2~~.

**5. (Withdrawn)** A vector comprising the nucleic acid molecule of Claim 4.

**6. (Currently Amended)** A pharmaceutical composition comprising the peptide of Claim 1 ~~or 2~~, for inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

**7. (Original)** The pharmaceutical composition of Claim 6, which is used as a cancer vaccine.

**8. (Withdrawn – Currently Amended)** An EGFR-reactive cytotoxic T lymphocyte which recognizes a complex between the peptide of Claim 1 ~~or 2~~ and an HLA molecule.

**9. (Withdrawn – Currently Amended)** A method for inducing an EGFR-reactive cytotoxic T lymphocyte using the peptide of Claim 1-~~or 2~~.

**10. (Withdrawn - Currently amended)** An antibody which specifically recognizes the peptide of Claim 1-~~or 2~~.

**11. (Withdrawn)** A nucleic acid molecule encoding the polypeptide of Claim 3.

**12. (Withdrawn)** A vector comprising the nucleic acid molecule of Claim 11.

**13. (Previously Presented)** A pharmaceutical composition comprising the peptide of Claim 3, for inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

**14. (Previously Presented)** The pharmaceutical composition of Claim 13, which is used as a cancer vaccine.

**15. (Withdrawn)** A pharmaceutical composition comprising the nucleic acid molecule of Claim 4, for inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

**16. (Withdrawn)** The pharmaceutical composition of Claim 15, which is used as a cancer vaccine.

**17. (Withdrawn)** An EGFR-reactive cytotoxic T lymphocyte which recognizes a complex between the polypeptide of Claim 3 and an HLA molecule.

**18. (Withdrawn)** A method for inducing an EGFR-reactive cytotoxic T lymphocyte using the polypeptide of Claim 3.

**19. (Withdrawn)** An antibody which specifically recognizes the polypeptide of Claim 3.